Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Change in Accured Expenses (2019 - 2025)

Bioadaptives' Change in Accured Expenses history spans 7 years, with the latest figure at $26687.0 for Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 74.47% year-over-year to $26687.0; the TTM value through Sep 2025 reached $60852.0, up 1039.98%, while the annual FY2024 figure was $44831.0, 9638.51% up from the prior year.
  • Change in Accured Expenses for Q3 2025 was $26687.0 at Bioadaptives, up from $12265.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $109110.0 in Q3 2021 and bottomed at -$29951.0 in Q4 2023.
  • The 5-year median for Change in Accured Expenses is $12358.0 (2025), against an average of $26661.1.
  • The largest annual shift saw Change in Accured Expenses skyrocketed 11289.35% in 2021 before it crashed 358.76% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at $107924.0 in 2021, then crashed by 89.27% to $11575.0 in 2022, then tumbled by 358.76% to -$29951.0 in 2023, then skyrocketed by 131.86% to $9542.0 in 2024, then soared by 179.68% to $26687.0 in 2025.
  • Per Business Quant, the three most recent readings for BDPT's Change in Accured Expenses are $26687.0 (Q3 2025), $12265.0 (Q2 2025), and $12358.0 (Q1 2025).